The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment

• Get our breaking news email, free app or daily news podcast

Thousands of women could be left without vital breast cancer and endometriosis medicine when AstraZeneca removes its treatment from the Pharmaceutical Benefits Scheme (PBS) and the private market, experts warn.

Zoladex will no longer be available in Australia from November, as the ABC first reported, but some existing patients will still be able to access it for an additional six months.

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year

• Business live – latest updates

GSK’s new boss, Luke Miels, has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications.

The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash.